Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection
about
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model systemPreventing and treating secondary bacterial infections with antiviral agentsANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.Antiviral strategies for pandemic and seasonal influenzaEmerging antiviral strategies to interfere with influenza virus entry.An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection.Viral and bacterial interactions in the upper respiratory tractThe Effect of Probiotic Treatment on Patients Infected with the H7N9 Influenza Virus.Influenza A virus entry inhibitors targeting the hemagglutinin.Alternative approaches to antiviral treatments: focusing on glycosylation as a target for antiviral therapy.Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections.Broad-spectrum antiviral agents.The trans-sialidase, the major Trypanosoma cruzi virulence factor: Three decades of studies.Treating Influenza Infection, From Now and Into the FutureRe-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies
P2860
Q30387832-B3FFAAE4-550D-4EF5-84CA-540FAF081D33Q30398935-B36F554C-0082-4965-BC12-4A142590CEF1Q30401260-37077BCE-C87A-4139-A317-9B3E2843DD35Q30404586-D795A720-1990-42F2-9E97-17EFEB8DFBF9Q30408116-83F754CC-3536-44D2-9727-9A943191DD3CQ30432421-D6C07A8D-B0E9-499A-8EE6-EF1DAB5CE4A9Q31170809-5C1DECD4-8E92-4FED-A3AE-C5A8248CCBD8Q34550727-FAD07CF0-ADC2-4B3D-A080-EBF6B22584BFQ35961347-72FD467B-CBB6-4DCF-B671-D5C5A3CEDB56Q36586898-50E31CCA-8467-46B9-9988-469C5F554E17Q37774669-1C4712B6-F94C-48FB-A780-39C200D87E30Q37913363-EB908471-2C4F-4AEC-AA49-8DE5198BCC61Q38519881-5C2AC5BF-86DB-4194-BD7F-22F05F229C88Q38557287-1DDEB23F-95AF-479C-822D-0BC2285CD1DCQ57158941-F1D7D5D1-21A9-420E-9BBC-6563B14F700FQ57930420-3B92DD0E-0BD2-4EE3-8F86-BF86F01DFB4D
P2860
Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Sialidase-based anti-influenza ...... condary pneumococcal infection
@ast
Sialidase-based anti-influenza ...... condary pneumococcal infection
@en
type
label
Sialidase-based anti-influenza ...... condary pneumococcal infection
@ast
Sialidase-based anti-influenza ...... condary pneumococcal infection
@en
prefLabel
Sialidase-based anti-influenza ...... condary pneumococcal infection
@ast
Sialidase-based anti-influenza ...... condary pneumococcal infection
@en
P2093
P2860
P356
P1476
Sialidase-based anti-influenza ...... condary pneumococcal infection
@en
P2093
Jeffrey L Larson
Kellie Jensen
Laura M Aschenbrenner
Maria Hedlund
P2860
P304
P356
10.1086/651170
P407
P577
2010-04-01T00:00:00Z